glp 1 vs glp 1/gip Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? Upcoming wave of hormone-based therapies
Description
6.7% of patients taking GLP-1 developed NAION compared to 0.8% of patients taking other medications
Mann JFE, rsted DD, Brown-Frandsen K et al
Solution: Drink water regularly throughout the day
Developing GLP-1 therapies with proven cardiovascular outcomes and metabolic health benefits addresses broader patient populations requiring comprehensive cardiometabolic care
Some patients also experience headaches and muscle pain
Some providers recommend keeping it in your mouth as long as possible
